CA2396351C - New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders - Google Patents

New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders Download PDF

Info

Publication number
CA2396351C
CA2396351C CA002396351A CA2396351A CA2396351C CA 2396351 C CA2396351 C CA 2396351C CA 002396351 A CA002396351 A CA 002396351A CA 2396351 A CA2396351 A CA 2396351A CA 2396351 C CA2396351 C CA 2396351C
Authority
CA
Canada
Prior art keywords
antipsychotic
antipsychotic agent
methyl
indol
dioxino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002396351A
Other languages
English (en)
French (fr)
Other versions
CA2396351A1 (en
Inventor
Karen Lovell Marquis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2396351A1 publication Critical patent/CA2396351A1/en
Application granted granted Critical
Publication of CA2396351C publication Critical patent/CA2396351C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002396351A 1999-12-10 2000-12-07 New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders Expired - Lifetime CA2396351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10
PCT/US2000/033060 WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Publications (2)

Publication Number Publication Date
CA2396351A1 CA2396351A1 (en) 2001-06-14
CA2396351C true CA2396351C (en) 2009-11-10

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396351A Expired - Lifetime CA2396351C (en) 1999-12-10 2000-12-07 New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders

Country Status (20)

Country Link
EP (1) EP1235570A2 (no)
JP (1) JP5557409B2 (no)
KR (1) KR100772854B1 (no)
CN (1) CN1230164C (no)
AR (1) AR026756A1 (no)
AU (1) AU784211B2 (no)
BR (1) BR0016168A (no)
CA (1) CA2396351C (no)
CZ (1) CZ20021880A3 (no)
EA (1) EA005002B1 (no)
HK (1) HK1045942A1 (no)
HU (1) HUP0203309A3 (no)
IL (2) IL149669A0 (no)
MX (1) MXPA02005649A (no)
NO (1) NO20022739D0 (no)
NZ (1) NZ519381A (no)
PL (1) PL355292A1 (no)
TW (1) TWI222864B (no)
WO (1) WO2001041750A2 (no)
ZA (1) ZA200205484B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
BRPI0608353A2 (pt) 2005-02-17 2009-12-01 Wyeth Corp derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfundidos
BRPI0907570A2 (pt) * 2008-02-13 2019-09-24 Targacept Inc agonistas alfa7 nicotínico e antipsicóticos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
NZ519381A (en) 2004-04-30
NO20022739L (no) 2002-06-07
KR100772854B1 (ko) 2007-11-02
CN1230164C (zh) 2005-12-07
AU784211B2 (en) 2006-02-23
KR20030016207A (ko) 2003-02-26
BR0016168A (pt) 2002-08-20
EP1235570A2 (en) 2002-09-04
WO2001041750A3 (en) 2002-02-14
CN1409633A (zh) 2003-04-09
PL355292A1 (en) 2004-04-05
TWI222864B (en) 2004-11-01
JP5557409B2 (ja) 2014-07-23
AU1949001A (en) 2001-06-18
EA200200656A1 (ru) 2002-12-26
HUP0203309A3 (en) 2004-12-28
HK1045942A1 (zh) 2002-12-20
HUP0203309A2 (hu) 2003-01-28
EA005002B1 (ru) 2004-10-28
AR026756A1 (es) 2003-02-26
NO20022739D0 (no) 2002-06-07
WO2001041750A2 (en) 2001-06-14
JP2003516350A (ja) 2003-05-13
ZA200205484B (en) 2003-12-31
IL149669A0 (en) 2002-11-10
CZ20021880A3 (cs) 2002-08-14
CA2396351A1 (en) 2001-06-14
IL149669A (en) 2006-06-11
MXPA02005649A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
JP2007516275A (ja) 認知増強および精神病性障害のための治療的組合せ
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US20070238725A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
US6350773B1 (en) Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
CA2649590A1 (en) Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
CA2396351C (en) New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
AU2004246820B2 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
Cheng et al. Dopamine hypothesis
MXPA05013580A (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201207